Triple-receptor agonist · Investigational

Reta 30mg

Retatrutide · 30mg vial

Retatrutide is a single investigational molecule designed to activate three receptors: GIP, GLP-1 and glucagon. These pathways influence appetite, glucose handling and energy balance.

Pricing · per unit

Mix & match any vials — 2–4 −10%, 5+ −15%
Retail1 unitR912
2–4−10%R821
5+−15%R775

In stock

How it works

The two incretin signals act on nutrient and appetite pathways, while glucagon adds a separate metabolic signal. It is being studied as a once-weekly treatment in controlled clinical trials.

Research context

Phase 2 and phase 3 studies are evaluating obesity and metabolic disease. Lilly states that retatrutide remains investigational; results from a trial do not establish a protocol for unapproved vials.

Vial contents & handling

  • 30mg retatrutide
  • Single lyophilised vial

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — ask us on WhatsApp ↗

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

Research reference dosage

30mg vial · 3ml water · 10mg/ml
LevelAmountU100 unitsFrequency
Beginner2mg20 unitsOnce weekly or split 2× weekly · any time
Intermediate4–6mg40–60 unitsOnce weekly or split 2× weekly · any time
Advanced8–12mg80–120 unitsOnce weekly or split 2× weekly · any time

Fixed 3ml · U100 device (1 unit = 0.01ml). For split weekly schedules, use half the listed full-amount units per administration. Research reference only—not human-use guidance.

Dosing status: No approved beginner dose or consumer titration schedule. Clinical-trial dose levels are study-design details, not instructions for these vials.

References

Guides

Research use only · Not for human or veterinary consumption · Not for self-administration